Strategic Collaborations AvantGen has a history of entering strategic collaborations with biotechnology partners to accelerate antibody development efforts. Leveraging these partnerships could open up new avenues for sales expansion through collaborative projects and joint product offerings.

Innovative Antibody Technologies With innovative platforms such as the NK cell engager technology and human antibodies for COVID-19 diagnosis and treatment, AvantGen offers cutting-edge antibody solutions. Highlighting these technologies in sales pitches can attract partners looking for advanced biotechnology solutions.

Experienced Leadership Team The appointment of industry veterans like Jordon Wang as the Chief Operating Officer and Mark F. Kubik as the Chief Business Officer showcases AvantGen's commitment to strong leadership. Capitalizing on the credibility and experience of these key personnel in sales engagements can build trust and facilitate business growth.

Government Grants and Awards AvantGen's recognition through SBIR Phase II grants from prestigious institutions like the National Institutes of Health (NIH) signifies the company's cutting-edge research capabilities. Highlighting these achievements can instill confidence in potential partners and investors, paving the way for sales conversions.

Diverse Portfolio and Revenue Range With a diverse array of antibody-based products ranging from anti-cancer therapeutics to neuroscience antibodies, AvantGen caters to various segments within the biotechnology industry. This diversified portfolio, coupled with a revenue range of $0 - 10M, presents opportunities for flexible pricing strategies and customized solutions to attract a wider customer base.